{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:03Z","timestamp":1793293863241,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>National Immunization Technical Advisory Groups recommend long-acting monoclonal antibody prophylaxis for the prevention of respiratory syncytial virus (RSV) disease for children at high risk in the first season, regardless of RSV vaccination during pregnancy, and for those who remain at increased risk in the second season.<\/jats:p><\/jats:sec>Objective<\/jats:title>This study assessed which groups of children with chronic medical conditions (CMCs) are at higher risk of RSV hospitalization during their first and second RSV seasons.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective, population-based, season-stratified cohort analysis was conducted among children who were born between April 1, 2013, and March 31, 2023, in British Columbia, Canada (population of 5.7 million in 2024), and were enrolled in the provincial medical service plan and followed up until the day before their third RSV season or April 1, 2024, whichever occurred first.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Any CMC diagnosed in the first 2 years of life.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Respiratory syncytial virus\u2013related hospitalizations.<\/jats:p><\/jats:sec>Results<\/jats:title>The final cohort consisted of 431\u202f937 children (32\u202f959 [7.6%] born at &amp;lt;37 weeks\u2019 gestation; 222\u202f207 boys [51.4%]) followed up for a median of 728 days (IQR, 642-729 days), including 25\u202f452 children (5.9%) diagnosed with at least 1 of 1116 distinct CMCs. In total, 4567 children (1.1%) experienced a combined total of 4592 RSV hospitalizations, combining data from the first and second RSV seasons. In the first RSV season, the RSV hospitalization rate per 1000 person-years for children with CMCs was 15.9 (95% CI, 14.2-17.6) and for children without CMCs was 8.0 (95% CI, 7.7-8.3). In the second RSV season, the RSV hospitalization rate per 1000 person-years for children with CMCs was 7.8 (95% CI, 6.7-8.8) and for children without CMCs was 2.2 (95% CI, 2.1-2.3). Children with multisystem CMCs, particularly those affecting the respiratory, cardiovascular, or gastrointestinal systems, had second-season RSV hospitalization rates that were at least 2-fold higher than the rate among all children in the first season. Second-season rates among children with Down syndrome or those who were born prematurely (&amp;lt;28 weeks of gestation) were 5-fold higher than for all children in the first season.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This population-based retrospective cohort study identified specific groups of higher-risk children with CMCs who could most benefit from prophylaxis with long-acting monoclonal antibodies in their first and second RSV seasons. This study supports expanded eligibility criteria for long-acting monoclonal antibody prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.19410","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T15:00:17Z","timestamp":1751986817000},"page":"e2519410","source":"Crossref","is-referenced-by-count":10,"title":["RSV Hospital Admissions During the First 2 Seasons Among Children With Chronic Medical Conditions"],"prefix":"10.1001","volume":"8","author":[{"given":"Marina","family":"Vi\u00f1eta Paramo","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Women+ and Children\u2019s Health, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Bone","sequence":"additional","affiliation":[{"name":"British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Vaccine Evaluation Center, British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Bettinger","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Vaccine Evaluation Center, British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Seaton","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Solimano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew O.","family":"Wiens","sequence":"additional","affiliation":[{"name":"British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"},{"name":"Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta M.","family":"Skowronski","sequence":"additional","affiliation":[{"name":"Immunization Programs and Vaccine Preventable Diseases Service, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Sbihi","sequence":"additional","affiliation":[{"name":"Data and Analytics Services, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal M.","family":"Lavoie","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Women+ and Children\u2019s Health, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"10340","key":"zoi250602r1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"zoi250602r2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.prrv.2018.12.001","article-title":"Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.","volume":"33","author":"Luna","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"2","key":"zoi250602r3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1666","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","volume":"134","year":"2014","journal-title":"Pediatrics"},{"issue":"16","key":"zoi250602r4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250602r5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomized controlled trials.","volume":"7","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"34","key":"zoi250602r6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"zoi250602r11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"2","key":"zoi250602r12","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14083","article-title":"Age-specific predictors of disease severity in children with respiratory syncytial virus infection beyond infancy and through the first 5 years of age.","volume":"35","author":"Brenes-Chacon","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"zoi250602r13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/cid\/cir928","article-title":"Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study.","volume":"54","author":"Kristensen","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi250602r14","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/ppul.25435","article-title":"Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.","volume":"56","author":"Shmueli","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"zoi250602r15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-061803","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","volume":"152","author":"Caserta","year":"2023","journal-title":"Pediatrics"},{"issue":"2","key":"zoi250602r16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jamapediatrics.2017.3792","article-title":"Association of age with risk of hospitalization for respiratory syncytial virus in preterm infants with chronic lung disease.","volume":"172","author":"Winterstein","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"1","key":"zoi250602r18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2431-14-199","article-title":"Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation.","volume":"14","author":"Feudtner","year":"2014","journal-title":"BMC Pediatr"},{"issue":"3","key":"zoi250602r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150416","article-title":"Incidence of hospitalization for respiratory syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data.","volume":"11","author":"Pisesky","year":"2016","journal-title":"PLoS One"},{"issue":"1248905","key":"zoi250602r20","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1248905","article-title":"Cohort profile: the British Columbia COVID-19 Cohort (BCC19C)\u2014a dynamic, linked population-based cohort.","volume":"12","author":"Wilton","year":"2024","journal-title":"Front Public Health"},{"issue":"S1","key":"zoi250602r22","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1093\/infdis\/jiaa751","article-title":"Risk factors for poor outcome or death in young children with respiratory syncytial virus\u2013associated acute lower respiratory tract infection: a systematic review and meta-analysis.","volume":"226","author":"Shi","year":"2022","journal-title":"J Infect Dis"},{"issue":"7","key":"zoi250602r23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/infdis\/jiy256","article-title":"Molecular characterization of respiratory syncytial virus in children with repeated infections with subgroup B in the Philippines.","volume":"218","author":"Okamoto","year":"2018","journal-title":"J Infect Dis"},{"issue":"11","key":"zoi250602r24","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70046","article-title":"Evaluating the economic and epidemiological impact of RSV hospitalizations in Southern Austria [Southern Austria Respiratory Syncytial Virus INpatient Investigation (ARNI Study)].","volume":"18","author":"Sever Yildiz","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"zoi250602r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100582","article-title":"Respiratory syncytial virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective observational study.","volume":"25","author":"Vi\u00f1eta Paramo","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"zoi250602r26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jamapediatrics.2023.1088","article-title":"Shifting epidemiology and severity of respiratory syncytial virus in children during the COVID-19 pandemic.","volume":"177","author":"Rao","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"3","key":"zoi250602r28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"8","key":"zoi250602r29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/jpids\/piad052","article-title":"Safety of re-dosing nirsevimab prior to RSV season 2 in children with heart or lung disease.","volume":"12","author":"Domachowske","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"zoi250602r30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/INF.0000000000004181","article-title":"Clinical practice patterns and risk factors for severe conditions in pediatric hospitalizations with respiratory syncytial virus in Japan: a nationwide analyses (2018-2022).","volume":"43","author":"Okubo","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"zoi250602r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2023-062574","article-title":"Respiratory syncytial virus\u2013associated hospitalizations among children <5 years old: 2016 to 2020.","volume":"153","author":"Curns","year":"2024","journal-title":"Pediatrics"},{"issue":"26","key":"zoi250602r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abd6421","article-title":"Community factors associated with local epidemic timing of respiratory syncytial virus: a spatiotemporal modeling study.","volume":"7","author":"Zheng","year":"2021","journal-title":"Sci Adv"},{"issue":"49","key":"zoi250602r34","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1016\/j.vaccine.2022.10.041","article-title":"Optimal respiratory syncytial virus intervention programmes using nirsevimab in England and Wales.","volume":"40","author":"Hodgson","year":"2022","journal-title":"Vaccine"},{"key":"zoi250602r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100629","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study.","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"zoi250602r7","unstructured":"Statement on the prevention of respiratory syncytial virus disease in infants. Government of Canada. 2024. Accessed May 31, 2024. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-statement-prevention-respiratory-syncytial-virus-disease-infants.html"},{"key":"zoi250602r8","unstructured":"Recomendaciones de utilizaci\u00f3n de nirsevimab para la temporada 2024-2025 en Espa\u00f1a. Consejo Interterritorial\u2014Sistema Nacional de Salud; 2024. Accessed September 27, 2024. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/Nirsevimab.pdf"},{"key":"zoi250602r9","unstructured":"Recommandations du Conseil sup\u00e9rieur des maladies infectieuses concernant l\u2019immunisation passive contre le RSV par des nouveaux anticorps monoclonaux. Conseil Superieur des Maladies Infectieuses. 2023. Accessed September 27, 2024. https:\/\/sante.public.lu\/dam-assets\/fr\/espace-professionnel\/recommandations\/conseil-maladies-infectieuses\/Infection-a-virus-respiratoire-syncitial-_RSV_\/17072023-recommandation-csmi-rsv-immunisation-vf.pdf"},{"key":"zoi250602r10","unstructured":"Respiratory syncytial virus (RSV) immunisation programme for infants and older adults: JCVI full statement, 11 September 2023. Department of Health & Social Care. 2023. Accessed September 27, 2024. https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-programme-jcvi-advice-7-june-2023\/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023"},{"key":"zoi250602r17","unstructured":"Respiratory virus detections in Canada. Government of Canada. Accessed August 4, 2021. https:\/\/www.canada.ca\/en\/public-health\/services\/surveillance\/respiratory-virus-detections-canada.html"},{"key":"zoi250602r21","unstructured":"Community Health Service Area boundaries: version 2022. Government of Canada. 2023. Accessed February 5, 2024. https:\/\/open.canada.ca\/data\/en\/dataset\/68f2f577-28a7-46b4-bca9-7e9770f2f357"},{"key":"zoi250602r27","unstructured":"Index of remoteness. Statistics Canada. Accessed May 20, 2025. https:\/\/www150.statcan.gc.ca\/n1\/pub\/17-26-0001\/172600012020001-eng.htm"},{"key":"zoi250602r33","unstructured":"Jones? J. Evidence to recommendations framework: nirsevimab updates. Presented at: Advisory Committee on Immunization Practices Meeting; August 3, 2023; Atlanta, Georgia. Centers for Disease Control and Prevention. Accessed November 5, 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/131586"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2836121\/vieta_paramo_2025_oi_250602_1751060242.30448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T15:00:23Z","timestamp":1751986823000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2836121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.19410","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}